Wolbert Jonathan G., Rajnik Michael, Swinkels Helena M., Higginbotham Karla
PBCGME
Uniformed Service University of the Health Sciences
Poliomyelitis, or polio, is an infection transmitted via the fecal-oral and oral-oral routes by the poliovirus. Today, polio primarily affects children younger than 5 in countries with poor water, sanitation, and hygiene infrastructure. While extremely rare outside these areas, polio presents a risk to populations with low vaccination rates, including in industrialized nations. The 2014 declaration deeming the global spread of polioviruses a public health emergency of international concern under the International Health Regulations remains in place.[WHO. Vaccine Position] Previously one of the most feared diseases in the world, polio caused widespread morbidity and mortality in children during multiple epidemics between the 1900s and 1960s. The incidence of polio began to decline following the development of the injectable polio vaccine (IPV) and oral polio vaccine (OPV). Intensified worldwide vaccination efforts starting in the 1980s by the World Health Organization (WHO) and partners under the Global Polio Eradication Initiative (GPEI) have almost completely eradicated the disease. Vaccination protocols worldwide now recommend administering at least 3 doses of IPV (IPV-only schedule) or at least 3 doses of bivalent OPV plus at least 2 doses of IPV (combined OPV-IPV schedule). The latter is recommended in countries where poliovirus incidence rates remain unchanged or are at risk of increasing. See StatPearls' companion article "Polio Vaccine" for more information on polio vaccinations. Healthcare professionals must maintain a high index of suspicion to diagnose acute poliomyelitis in patients who present with new-onset paralysis following a viral prodrome and are living in an endemic region or under-vaccinated population. The presentation of polio is highly variable, ranging from asymptomatic to a transient flu-like viral illness to paralysis, quadriplegia, and even respiratory failure and death. Many polio survivors experience a poor quality of life. Alternate diagnoses must be considered as polio is rare, and other more common diseases and conditions can present similarly. In particular, acute flaccid myelitis (AFM) presents with a polio-like syndrome. This condition is caused by epidemic enteroviral infections, most commonly enterovirus D68. As no antiviral treatment for acute poliomyelitis exists, prevention is critical. Paralytic deficits are often permanent, resulting in chronic pain, deformities, weakness, and eventual osteoporosis and fragility fracture. Between 25% and 40% of the estimated 12 to 20 million polio survivors worldwide will also develop postpolio syndrome (PPS). A diagnosis of PPS requires new-onset, progressive muscle weakness or fatiguability, mental fatigue, or pain in a patient diagnosed with poliomyelitis up to 40 years prior. PPS is not contagious and is rarely life-threatening, but it often affects patients' independence and quality of life. While the near eradication of polio represents a tremendous achievement for global public health, multiple challenges and delays remain. Vaccine-derived polioviruses (VDPVs) revert or recombine to wild-type neurovirulence and transmissibility, causing outbreaks and distrust in vaccination programs. Poliovirus typically escapes early detection; most infections are asymptomatic, and the characteristic paralysis occurs in a small minority of those it infects.[CDC. Polio_HCP] Delays in detecting circulating wild poliovirus (WPV) and VDPVs pose a significant risk to eradication efforts. Political unrest or indecision and declining or competing interests threaten efforts to eradicate the disease. Recent polio cases and the discovery of poliovirus in wastewater in industrialized nations emphasize that, until completely eradicated, polio remains a global risk.[GPEI. Polio Eradication] Clinicians should suspect polio in patients with acute-onset flaccid paralysis, decreased or absent tendon reflexes, and without sensory or cognitive deficits. to ensure appropriate diagnostic testing, surveillance, and public health follow-up at.[CDC. Polio_Clinical]
脊髓灰质炎,简称小儿麻痹症,是一种由脊髓灰质炎病毒通过粪口途径和口口途径传播的感染性疾病。如今,脊髓灰质炎主要影响水、环境卫生和个人卫生基础设施较差国家中5岁以下的儿童。虽然在这些地区以外极为罕见,但脊髓灰质炎对疫苗接种率较低的人群构成风险,包括工业化国家的人群。2014年宣布将脊髓灰质炎病毒的全球传播视为《国际卫生条例》规定的国际关注的突发公共卫生事件,这一认定仍然有效。[世界卫生组织。疫苗立场]脊髓灰质炎曾是世界上最令人恐惧的疾病之一,在20世纪初至60年代的多次疫情中,它在儿童中造成了广泛的发病和死亡。随着注射用脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎疫苗(OPV)的研制成功,脊髓灰质炎的发病率开始下降。20世纪80年代起,世界卫生组织(WHO)及其合作伙伴在全球根除脊髓灰质炎行动(GPEI)下加强了全球疫苗接种工作,几乎完全根除了这种疾病。现在,全球的疫苗接种方案建议至少接种3剂IPV(仅IPV方案)或至少3剂二价OPV加至少2剂IPV(联合OPV-IPV方案)。在脊髓灰质炎病毒发病率保持不变或有上升风险的国家,推荐采用后者。有关脊髓灰质炎疫苗接种的更多信息,请参阅StatPearls的配套文章“脊髓灰质炎疫苗”。对于在病毒前驱症状后出现新发麻痹、生活在流行地区或疫苗接种不足人群中的患者,医疗保健专业人员必须保持高度怀疑,以诊断急性脊髓灰质炎。脊髓灰质炎的表现高度可变,从无症状到短暂的流感样病毒疾病,再到麻痹、四肢瘫痪,甚至呼吸衰竭和死亡。许多脊髓灰质炎幸存者生活质量较差。由于脊髓灰质炎罕见,必须考虑其他诊断,其他更常见的疾病和病症可能有类似表现。特别是,急性弛缓性脊髓炎(AFM)表现为类似脊髓灰质炎的综合征。这种病症由流行性肠道病毒感染引起,最常见的是肠道病毒D68。由于不存在针对急性脊髓灰质炎的抗病毒治疗方法,预防至关重要。麻痹性缺陷通常是永久性的,会导致慢性疼痛、畸形